Blockchain Registration Transaction Record

Soligenix CEO Provides Updates on HyBryte(TM) in Benzinga Interview

Soligenix Inc.'s CEO, Christopher J. Schaber, shares updates on the company's focus on developing treatments for rare diseases like HyBryte(TM) in an exclusive interview with Benzinga. Learn more about the latest advancements in biopharmaceutical research.

Soligenix CEO Provides Updates on HyBryte(TM) in Benzinga Interview

This news highlights the innovative work being done by Soligenix Inc. in the field of biopharmaceuticals, specifically in the development of treatments for rare diseases. The potential success of HyBryte(TM) could have a significant impact on patients suffering from cutaneous T-cell lymphoma and other inflammatory diseases.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x4cde3130944954fd78f0457ca57768f756d7cd3f5763c161a7bdcf2b55d5ecd1
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintdashSsvY-d0de0fd217da86b22406594defe9b2ac